Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol.
clinical trials
motor neurone disease
neurology
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
23 03 2021
23 03 2021
Historique:
entrez:
24
3
2021
pubmed:
25
3
2021
medline:
20
5
2021
Statut:
epublish
Résumé
Motor neuron disease (MND) is a rapidly progressive and fatal neurodegenerative disorder with limited treatment options. The Motor Neuron Disease Systematic Multi-Arm Randomised Adaptive Trial (MND-SMART) is a multisite UK trial seeking to address the paucity in effective disease-modifying drugs for people with MND (pwMND). Historically, neurological trials have been plagued by suboptimal recruitment and high rates of attrition. Failure to recruit and/or retain participants can cause insufficiently representative samples, terminated trials or invalid conclusions. This study investigates patient-specific factors affecting recruitment and retention of pwMND to MND-SMART. Improved understanding of these factors may improve trial protocol design, optimise recruitment and retention. PwMND on the Scottish MND Register, Clinical Audit Research and Evaluation of MND (CARE-MND), will be invited to participate in a prospective observational cohort study that investigates factors affecting trial participation and attrition. We hypothesise that patient-specific factors will significantly affect trial recruitment and retention. Participants will complete the Hospital Anxiety and Depression Scale, 9-Item Patient Health Questionnaire and State-Trait Anxiety Inventory-Form Y to evaluate neuropsychiatric symptoms, the ALS-Specific Quality of Life Questionnaire-Brief Form and Centre for Disease Control and Prevention-Health-Related Quality of Life for quality of life and a novel study-specific questionnaire on Attitudes towards Clinical Trial Participation (ACT-Q). Clinical data on phenotype, cognition (Edinburgh Cognitive and Behavioural ALS Screen) and physical functioning (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised) will also be collated. Caregivers will complete the Brief Dimensional Apathy Scale. After 12 months, a data request to MND-SMART will evaluate recruitment and retention. Descriptive statistics will summarise and compare assessments and participants reaching impairment thresholds. Variable groupings: attitudes, quality of life, cognition, behaviour, physical functioning, neuropsychiatric and phenotype. Univariate and multivariable logistic regression will explore association with participation/withdrawal in MND-SMART; presented as ORs and 95% CIs. Ethical approval was provided by the West of Scotland Research Ethics Committee 3 (20/WS/0067) on 12 May 2020. The results of this study will be published in a peer-reviewed journal, presented at academic conferences and disseminated to participants and the public.
Identifiants
pubmed: 33757953
pii: bmjopen-2020-044996
doi: 10.1136/bmjopen-2020-044996
pmc: PMC7993162
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e044996Subventions
Organisme : Medical Research Council
ID : MR/L023784/2
Pays : United Kingdom
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.
Références
Muscle Nerve. 2018 Nov;58(5):646-654
pubmed: 30028537
J Clin Nurs. 2010 Jan;19(1-2):227-33
pubmed: 20500260
Trials. 2009 Jun 11;10:39
pubmed: 19519885
Amyotroph Lateral Scler. 2008 Oct;9(5):257-65
pubmed: 18608092
Clin Transl Radiat Oncol. 2018 Oct 04;13:44-49
pubmed: 30345398
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep;14(5-6):397-405
pubmed: 23421600
J Intern Med. 2002 Feb;251(2):156-68
pubmed: 11905591
BMJ. 2006 Apr 22;332(7547):969-71
pubmed: 16627519
J Neurol Neurosurg Psychiatry. 1992 Jul;55(7):536-41
pubmed: 1640227
Res Nurs Health. 2001 Dec;24(6):530-9
pubmed: 11746081
Amyotroph Lateral Scler Frontotemporal Degener. 2014 Mar;15(1-2):9-14
pubmed: 23781974
Eur Child Adolesc Psychiatry. 2002 Dec;11(6):266-72
pubmed: 12541005
Neurology. 2019 Apr 2;92(14):e1610-e1623
pubmed: 30850440
BMC Cardiovasc Disord. 2018 Nov 27;18(1):215
pubmed: 30482176
JAMA. 1999 Nov 10;282(18):1737-44
pubmed: 10568646
Amyotroph Lateral Scler Frontotemporal Degener. 2020 Nov;21(7-8):509-518
pubmed: 32573277
Public Health Rep. 1994 Sep-Oct;109(5):665-72
pubmed: 7938388
J Korean Med Sci. 2012 Feb;27(2):200-6
pubmed: 22323869
Ann Oncol. 2000 Aug;11(8):939-45
pubmed: 11038029
J Neurol. 2019 Apr;266(4):817-825
pubmed: 30805795
Postgrad Med. 2012 Sep;124(5):69-77
pubmed: 23095427
Control Clin Trials. 1987 Dec;8(4 Suppl):6S-30S
pubmed: 3326716
Ophthalmic Physiol Opt. 2014 Sep;34(5):502-8
pubmed: 24697967
Eur J Neurol. 2007 Sep;14(9):993-1001
pubmed: 17718691
Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):242-250
pubmed: 30889975
Neurology. 2013 Oct 8;81(15):1350-5
pubmed: 24005339
Health Qual Life Outcomes. 2011 Sep 29;9:82
pubmed: 21955749
Neurology. 2019 Jan 9;:
pubmed: 30626653
Cancer Nurs. 2003 Oct;26(5):376-84; quiz 385-6
pubmed: 14710799
Arch Neurol. 1996 Feb;53(2):141-7
pubmed: 8639063
Clin Neuropsychol. 2020 Feb;34(2):423-435
pubmed: 31154933
Br J Clin Psychol. 2001 Nov;40(4):429-34
pubmed: 11760618
J Neurol Neurosurg Psychiatry. 2016 Jun;87(6):663-9
pubmed: 26203157